Necrotizing fasciitis not always caused by bacteria but by a combination of tissue damage and a gene defect
A new Finnish-led study suggests that necrotizing fasciitis, a life-threatening inflammation of connective tissue that leads to tissue necrosis, may be caused by a gene defect. The findings offer hope for an effective new treatment for the disease that could avoid repeated surgery and amputations.
Necrotizing fasciitis is a soft tissue infection that rapidly leads to tissue necrosis. Around 50 patients a year are hospitalized with the disease in the Helsinki Metropolitan Area.
The disease can be treated with antibiotics and immediate surgery. However, the tissue damage caused by a strong inflammatory reaction is difficult to stop and patients often need to undergo emergency surgery. Necrotizing fasciitis can lead to a rapid need to amputate limbs, for example, even in previously healthy individuals.
Inflammation-activating gene defect located
Severe fasciitis has previously been thought to be caused by so-called carnivorous bacteria. Previously, the same Finnish researchers discovered a form of fasciitis that occurs as a result of a routine procedure or tissue damage combined with a gene defect in the patient's genome. This is when the body overreacts to tissue damage and causes inflammation. Bacteria are often not found at all or the infection is of minor importance.
Researchers have found an inflammation-activating defect in the NFKB1 gene in three Finnish and three foreign pediatric and adult patients with severe fasciitis. NFKB1 is one of the most important genes regulating the immune system.
The study investigated the mechanism of how a gene defect causes an excessive and violent inflammatory response. In patients, mild injury, surgery or infection had triggered an uncontrolled inflammatory reaction leading to severe deep tissue inflammation. The immune cells of patients carrying the gene defect secreted large amounts of mediators greatly accelerating inflammation.
Antirheumatic medicines help with inflammation
Several of the patients in the study have already been treated with immunosuppressive drugs. This has significantly reduced inflammation and prevented the disease from progressing and relapsing.
“With new gene-editing techniques, we were able to identify the nature of the inflammatory response and the mechanisms by which a gene defect causes a strong inflammatory response. We can control excessive inflammation with modern antirheumatic drugs. Due to the severity of their inflammation, some patients have already been treated with anti-inflammatory drugs with very promising results,” says Professor Kari Eklund from the HUS Inflammation Center who led the study.
"If these findings are confirmed, it will be important to investigate in the future whether targeting the mediators now found could help in the treatment of other necrotizing fasciitis."
In the next phase, the research team plans to find out how many people with fasciitis have a genetic predisposing factor to the disease.
Researchers from the University of Helsinki, the Institute of Biotechnology, Oulu University Hospital, the University of Oulu, the Finnish and Norwegian Institutes of Molecular Medicine, Argentina, the UK, and Germany also participated in the study led by HUS researchers.
Keywords
Contacts
Kari EklundProfessor of RheumatologyHUS Inflammation Center and the University of Helsinki
Tel:040 583 2866kari.eklund@hus.fiMikko SeppänenChief PhysicianHUS New Children's Hospital and Rare Diseases Center and the University of Helsinki
Tel:+358 50 427 9606mikko.seppanen@hus.fiLinks
About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats almost 700,000 patients every year. Our nearly 27,000 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Förebyggande av RS-virusinfektioner hos småbarn är under uppstart17.9.2024 09:07:30 EEST | Tiedote
I Finland kommer man i oktober–november att börja ge en ny slags antikropp, det vill säga nirsevimab som utvecklats mot RS-virus, till spädbarn under tre månader och barn under ett år som hör till en riskgrupp för allvarlig RS-virusinfektion. Målet med den är att förebygga största delen av fallen med allvarlig sjukdom hos och sjukhusvård av spädbarn till följd av RS-virus.
Pienten lasten RS-virusinfektioiden ehkäisy on alkamassa17.9.2024 09:07:30 EEST | Tiedote
Suomessa on loka-marraskuussa alkamassa RS-virusta vastaan kehitetyn uudenlaisen vasta-aineen eli nirsevimabin antaminen alle 3 kuukauden ikäisille vauvoille ja vakavan RSV-infektion riskiryhmiin kuuluville alle 1-vuotiaille lapsille. Sen tavoitteena on ehkäistä suurin osa RS-viruksen aiheuttamista imeväisikäisten vakavista sairastumisista ja sairaalahoidoista.
Antalet korrigerande operationer av näthinneavlossning ökar6.9.2024 09:08:15 EEST | Tiedote
Antalet akuta korrigerande operationer av näthinneavlossning vid HUS under veckoslut har ökat med över 60 procent under de senaste tio åren. Ökningen är ett resultat av den åldrande befolkningen, ett ökat antal starroperationer samt de allt vanligare linsoperationerna på grund av ålderssynthet.
Verkkokalvon irtauman korjausleikkaukset kasvussa6.9.2024 09:08:15 EEST | Tiedote
HUSissa viikonloppuisin tehtävien kiireellisten verkkokalvoirtauman korjausleikkausten määrä on kasvanut yli 60 prosenttia viimeisen kymmenen vuoden aikana. Kasvuun vaikuttavat väestön ikääntyminen, lisääntyneet kaihileikkaukset sekä yleistyneet ikänäön vuoksi tehtävät linssileikkaukset.
HUS har beredskap för mpox-smitta3.9.2024 12:59:50 EEST | Tiedote
Inom HUS har man förberett sig på att undersöka och behandla patienter som drabbats av mpox, det vill säga apkoppor. HUS laboratorium har vid behov beredskap att analysera mpox-prov från hela landet.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom